Table 1 Correlation between LINC01016 expression and patients’ clinicopathological characteristics.

From: ETS-1-activated LINC01016 over-expression promotes tumor progression via suppression of RFFL-mediated DHX9 ubiquitination degradation in breast cancers

Character

 

LINC01016 Expression

 

Number

High

Low

P

Age

<60

55

29

26

0.1040

≥60

46

32

14

Histological grade

I–II

49

27

22

0.3153

III

52

34

18

ER

Negative

51

35

16

0.1057

Positive

50

26

24

PR

Negative

53

28

25

0.1096

Positive

48

33

15

Her-2

Negative

46

29

17

0.6852

Positive

55

32

23

Ki-67

<15

45

19

26

0.0011

≥15

56

42

14

Tumer size(cm)

≤2 cm

40

21

19

0.2161

Å 2 cm

61

40

21

Lymphatic metastasis

Negative

49

18

31

<0.0001

Positive

52

43

9

Back to article page